Blurbs

Analysts Conflicted on These Healthcare Names: Cigna (CI), Intellia Therapeutics (NTLA) and Dynavax (DVAX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cigna (CIResearch Report), Intellia Therapeutics (NTLAResearch Report) and Dynavax (DVAXResearch Report).

Cigna (CI)

In a report released yesterday, Michael Newshel from Evercore ISI maintained a Hold rating on Cigna, with a price target of $230.00. The company’s shares closed last Friday at $266.90, close to its 52-week high of $272.81.

According to TipRanks.com, Newshel is ranked #2476 out of 7891 analysts.

Cigna has an analyst consensus of Moderate Buy, with a price target consensus of $267.89, representing a 4.7% upside. In a report issued on April 22, Deutsche Bank also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Intellia Therapeutics (NTLA)

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Intellia Therapeutics, with a price target of $75.00. The company’s shares closed last Friday at $47.57, close to its 52-week low of $47.02.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 5.2% and a 39.3% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $135.25 average price target, implying a 170.3% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $105.00 price target.

Dynavax (DVAX)

In a report released yesterday, Joshua Schimmer from Evercore ISI maintained a Buy rating on Dynavax, with a price target of $20.00. The company’s shares closed last Friday at $8.94, close to its 52-week low of $7.09.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 5.1% and a 46.6% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dynavax with a $24.00 average price target, a 184.4% upside from current levels. In a report issued on April 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos